Antiphospholipid antibodies are a heterogenous family of antibodies associated with an increased risk for venous and arterial thrombosis, recurrent fetal loss, and thrombocytopenia. Several kindreds have been described with a familial form of the antiphospholipid antibody syndrome, confirming an inherited tendency to antibody formation. In these patients, autoantibodies that bind to proteins involved in normal hemostasis (e.g., prothrombin) are associated with an increased thrombotic risk. Antiphospholipid antibodies are also frequently seen in patients with vascular grafts who sustain thrombotic occlusions. Bovine thrombin is commonly used during vascular surgery, and we have shown that most patients exposed to bovine thrombin during cardiovascular surgery develop elevated antibody levels to several bovine and human coagulation proteins, as well as elevated antiphospholipid antibody levels. We hypothesize that different groups of patients with antiphospholipid antibodies and thrombotic complications share a common clinical phenotype that has developed in response to distinct etiologic mechanisms. To probe the pathophysiologic mechanisms of these antibodies, we propose to investigate two prothrombotic antibody subsets frequently identified in patients with autoantibodies by the following aims. First, we will define the molecular interactions of antiprothrombin autoantibodies with prothrombin and determine the functional and clinical significance of these autoantibodies. Epitopes recognized by antiprothrombin autoantibodies will be identified. Functional consequences of antibody binding to prothrombin will be determined and correlated to thrombotic events. Second, we will investigate the mechanisms whereby antiphospholipid autoantibodies interfere with the anticoagulant mechanisms of activated protein C. The functional consequences of antiphospholipid autoantibodies on the inactivation of factor Va by the activated protein C complex will be characterized and correlated to clinical outcome. Third, antiphospholipid antibodies that develop in patients exposed to bovine thrombin will be compared to antiphospholipid autoantibodies for antiprothrombin activity as well as inhibition of the activated protein C complex. These studies will improve our understanding of the role(s) of distinct antibody subsets in producing a hypercoagulable state in different patient subsets with antiphospholipid antibody syndromes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24AI001603-04
Application #
6510027
Study Section
Allergy & Clinical Immunology-1 (AITC)
Program Officer
Prograis, Lawrence J
Project Start
1999-04-01
Project End
2004-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
4
Fiscal Year
2002
Total Cost
$99,249
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
O'Shea, Susan I; Arcasoy, Murat O; Samsa, Gregory et al. (2008) Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. J Thromb Thrombolysis 26:14-21
Rand, Jacob H; Wu, Xiao-Xuan; Lapinski, Robert et al. (2004) Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 104:2783-90
Larned, Zoe L; O'Shea, Susan I; Ortel, Thomas L (2003) Heparin-induced thrombocytopenia: clinical presentations and therapeutic management. Clin Adv Hematol Oncol 1:356-64
Perry, Stephanie L; O'Shea, Susan I; Ortel, Thomas L (2003) Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time. Blood Coagul Fibrinolysis 14:601-4
Perry, Stephanie L; Ortel, Thomas L (2003) Clinical and laboratory evaluation of thrombophilia. Clin Chest Med 24:153-70
O'Shea, Susan I; Ortel, Thomas L (2002) Issues in the utilization of low molecular weight heparins. Semin Hematol 39:172-8
O'Shea, Susan I; Sands, Jeffrey J; Nudo, Sybil A et al. (2002) Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol 69:72-3
Izumi, Tomonori; Pound, Mary L; Su, Zuowei et al. (2002) Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids. Thromb Haemost 88:620-6
Su, Zuowei; Izumi, Tomonori; Thames, Elizabeth H et al. (2002) Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med 139:349-56
Sands, J J; Nudo, S A; Moore, K D et al. (2001) Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis. ASAIO J 47:507-10

Showing the most recent 10 out of 13 publications